The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
September 1st 2025
Research reveals that increased sedentary time significantly impacts neurodegeneration and cognitive decline in older adults, especially those genetically at risk for Alzheimer’s.
Crenezumab Phase 3 CREAD Trials in Alzheimer Disease Discontinued By Roche
January 30th 2019The Independent Monitoring Committee’s interim analysis suggested that the treatment was unlikely to meet the trials’ primary end point of change from baseline in Clinical Dementia Rating-Sum of Boxes score.
SPRINT-MIND Shows No Benefit for Dementia Risk With Intensive Blood Pressure Strategy
January 29th 2019Despite the non-significant differences between groups, a slight trend toward a dementia risk reduction has led to the Alzheimer’s Association providing funds for a follow-up extension trial, dubbed SPRINT-MIND 2.0.
Challenges and Excitement in Alzheimer Disease
January 23rd 2019The director of the Center for Neurodegeneration and Translational Neuroscience and director emeritus, Cleveland Clinic Lou Ruvo Center for Brain Health, shared thoughts on his hope for the future of Alzheimer disease, among other topics.
Costantino Iadecola, MD: Cognitive Reserve in Alzheimer Disease
January 23rd 2019The Anne Parrish Titzell Professor of Neurology and Neuroscience at Weill Cornell Medicine’s Feil Family Brain and Mind Research Institute discussed how to make the decision about who will end developing Alzheimer and who will not when amyloid buildup occurs.
Dabigatran to be Assessed in Alzheimer Disease in BEACON Study
January 15th 2019The direct thrombin inhibitor is planned to be evaluated for its effect on the neurodegenerative disease in a trial of 40 to 60 patients with MCI and Alzheimer, led by researchers at the University of Rhode Island.
Bryostatin Shows Some Effect in Moderate to Severe Alzheimer Disease
December 21st 2018Although the therapy did not achieve significance for the primary end point in the full data set, a pre-specified exploratory analysis implemented in a post-hoc framework did provide evidence of significant benefit for the 20-μg dose.